Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018

Jacksonville, FL – May 30, 2018 — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET on Wednesday, June 6, 2018. The conference will be held at …

Espero BioPharma to Present at BIO CEO & Investor Conference on February 13, 2018

Jacksonville, FL and Irvine, CA – February 7, 2018 – Espero BioPharma, a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the BIO CEO & Investor Conference on Tuesday, February 13th, 2018 at 10:00 AM ET. The conference will be held …

Area company Espero looks to hold trials for new drugs

Jacksonville, FL – January 3, 2018 (The Florida Times Union) – In 2014 Quang Pham founded Espero Pharmaceuticals, which the Jacksonville Business Journal called “the fastest-growing company in Jacksonville” last year. Now the company, renamed Espero BioPharma after a merger, is preparing to launch new clinical trials for two drugs Pham, its chairman and CEO, believes can become “standards of …

Espero BioPharma to Present at Biotech Showcase on January 9, 2018

Jacksonville, FL and Irvine, CA – January 3, 2018 — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the Biotech Showcase 2018 on January 9th, 2018 at 11:45 AM PT / 2:45 PM ET. The conference will be held …

Espero BioPharma Provides Corporate Update and 2018 Objectives

JACKSONVILLE, Fla. and IRVINE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced a strategic update on its clinical and regulatory strategies for tecarfarin, an oral anticoagulant (OAC). Tecarfarin and budiodarone were added to Espero’s product pipeline through the company’s merger with …

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected to occur in the second …

Armetheon Announces European Medicines Agency’s Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 14, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has received advice from the European Medicines Agency (EMA) Scientific Advice Working Group (SAWG) for the development of its novel oral anticoagulant tecarfarin. The SAWG advised that Armetheon can conduct a single1000 patient pivotal study prior …

Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral antiarrhythmic budiodarone

MENIO PARK, Calif., Feb. 13, 2017 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced the issuance on January 24, 2017 by the U.S. Patent and Trademark Office (USPTO) of a new patent covering the company’s novel oral antiarrhythmic, budiodarone, the only known novel anti-arrhythmic in clinical development. The new U.S. Patent No. …

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s annual JP Morgan Healthcare Conference …

Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO™ (Nitroglycerin) Sublingual Powder in the U.S.

New Short-Acting Nitrate Powder Now Available in Single Dose Packets 
for Acute Relief of an Angina Pectoris Attack JACKSONVILLE, Fla. (Sept. 27, 2016) – Espero Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced the commercial availability of GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. GONITRO™ …